Estimating the effects of time-varying treatments: Incidence of fractures among postmenopausal Japanese women

Epidemiology

Volumn 18, Issue 5, 2007, Pages 529-536

  Tanaka, Shiro ^a   Matsuyama, Yutaka ^a   Shiraki, Masataka ^b   Ohashi, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; CONJUGATED ESTROGEN; ETIDRONIC ACID; GESTAGEN; NONOXINOL 9; RISEDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MONOTHERAPY; MORBIDITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPHOSPHONATES; EPIDEMIOLOGIC METHODS; ESTROGENS, CONJUGATED (USP); FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; JAPAN; MIDDLE AGED; MODELS, STATISTICAL; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; TIME FACTORS; VITAMIN D;

EID: 34547876097     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181271ae2     Document Type: Article

References (30)

1. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998.
2. Rosenbaum PR. The consequences of adjustment for a concomitant variable that has been affected by the treatment. J R Statist Soc A. 1984;147:656-666.
3. Robins JM. The control of confounding by intermediate variables. Stat Med. 1989;8:679-701.
4. Robins JM, Greenland S, Hu F. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. J Am Statist Assoc. 1999;94:687-700.
5. Robins JM. Causal inference from complex longitudinal data. In: Berkane M, eds. Latent Variable Modeling and Applications to Causality. Berlin: Springer-Verlag; 1997:69-117.
6. Robins JM, Blevins D, Ritter G, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology. 1992;3:319-336.
7. NIH Consensus Development Panel on Osteoporosis. Prevention, diagnosis and therapy consensus conference. JAMA. 2001;285:785-795.
8. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897.
9. Orimo H. New diagnostic criteria of primary osteoporosis. Clin Calcium. 2001;11:1133-1139.
10. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
11. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Commun Statist. 1994;23:2379-2412.
12. Fukunaga M, Nakamura T, Shiraki M, et al. Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab. 2004;22:104-110.
13. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
14. Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat. 1978;6:34-58.
15. Bishop YMM, Fienberg SE, Holland PW. Discrete Multivariate Analysis: Theory and Practice. 1st ed. Cambridge, MA: MIT Press; 1975.
16. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: An randomized trials with compliance information: An application to the multiple risk factor intervention application to the multiple risk factor intervention trial. Controlled Clin Trials. 1993;14:79-97.
17. Häuselmann HJ, Rizzoli AR. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int. 2003;14:2-12.
18. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fracture. Lancet. 1996;348:1535-1541.
19. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
20. Writing Group for the Women's Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
21. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
22. Pasco JA, Kotowicz MA, Henry MJ, et al. Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study. Osteoporos Int. 2004;15:434-438.
23. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone. 2004;34:728-735.
24. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause. 2003;10:412-419.
25. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int. 1999;10:183-192.
26. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate calcitonin, alfacalcidol, vitamin K2 in postmenopausal women with osteoporosis The Yamaguchi Osteoporosis Prevention Study. Am J Med. 2004;117:549-555.
27. Kushida K, Shiraki M, Nakamura T, et al. on behalf of the Alendronate/Alfacalcidol Fracture Intervention Study Group. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp. 2002;63:606-620.
28. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Intern. 1994;54:370-376.
29. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double blind prospective study. Endocr J. 1996;43:211-220.
30. Recker RR, Davies KM, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med. 1999;130:897-904.